Sustained good response to rituximab in acquired von Willebrand syndrome

Blood Coagul Fibrinolysis. 2024 Apr 1;35(3):147-149. doi: 10.1097/MBC.0000000000001278. Epub 2024 Apr 5.

Authors

Jayna Mistry¹, Gillian Clare Lowe, Will Lester, Charles Llewellyn Percy

Affiliation

¹ West Midlands Adult Comprehensive Care Haemophilia & Thrombosis Centre, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, UK.

PMID: 38557934
DOI: 10.1097/MBC.0000000000001278

No abstract available

MeSH terms

Humans
Rituximab / therapeutic use
von Willebrand Diseases* / drug therapy
von Willebrand Factor / therapeutic use

Substances

Rituximab
von Willebrand Factor